Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) consists of a heterogeneous group of patients with a wide range of survival times, requiring further prognostic stratification to facilitate treament allocation. We evaluated the prognostic value of for staging were retrospectively enrolled from 7 university hospitals. The patients were further divided into two groups according to the extent of disease, as intrahepatic or extrahepatic.
INTRODUCTION
Liver cancer is the second most common cause of cancer-related deaths in men and the sixth in women worldwide (1) . The Barcelona Clinic Liver Cancer (BCLC) staging system is the most commonly used for predicting survival by international guidelines of hepatocellular carcinoma (HCC) management (2) . Performance status, Child-Pugh score, tumor size, multiple tumors, vascular invasion, nodal spread, and extrahepatic metastasis can be classify patients into four stages -early (A), intermediated (B), advanced (C), and end-stage (D) (3) . The BCLC staging system includes a wide spectrum of diseases with different prognoses, especially in intermediate to advanced stages (4, 5) .
BCLC stage C includes patients with portal vein invasion, lymph node or distant metastasis, Eastern Cooperative Group Performance Status 1 or 2, and Child-Pugh A or B. Sorafenib, the multitargeted tyrosine kinase inhibitor, remains the the only standard of care that can be offered for this stage, although clinically various local and systemic therapies are given for palliative purposes (6) (7) (8) . In some BCLC C patients with portal vein tumor thrombosis, long-term survival can be achieved by surgical resection followed by postoperative transarterial chemoembolization (9) . Studies have proposed a need for new prognostic systems for better prediction of patient survival and facilitation of treatment allocation (2, 10, 11) .
Despite the poor sensitivity for well differentiated HCC, 18 F-FDG PET/CT or PET has been helpful for the detection of moderately to poorly differentiated or advanced HCC (12-18) and particularly, for the prediction of prognosis of patients (19) . To date, the majority of studies regarding the prognostic role of 18 F-FDG PET have focused on patients with early stage HCC (20) (21) (22) (23) . There are only a few studies that enrolled patients with advanced stage, and most of them included small populations (24, 25) . In this study, we evaluated the prognostic value of 18 F-FDG uptake on pretreatment PET/CT scans in a larger number of patients with BCLC stage C HCC from a multicenter retrospective cohort.
MATERIALS AND METHODS

Study Population
The institutional review boards of the seven participating university hospitals (Dongsan Medical Center, Incheon St. Mary's Hospital, Kyung Hee University Hospital, Samsung Medical Center, Seoul St. Mary's Hospital, Uijeongbu St. Mary's Hospital, and Yonsei University Health System) approved this retrospective multicenter study, and the requirement to obtain informed consent was waived. We retrospectively reviewed the medical records of 847 consecutive patients with HCC who underwent pre-treatment staging with 18 F-FDG PET/CT between January 2009 and December 2010, and the images were sent for review at a single institution. All patients were assessed at presentation using the BCLC staging classification, laboratory findings, and several imaging modalities (CT, magnetic resonance imaging [MRI] and PET/CT).
Out of a total 847 HCC patients, 291 were enrolled in the study and met the following eligibility criteria: diagnosed as HCC with BLCL stage C, PET/CT performed before the start of initial treatment, and no previous history of other malignancy. The patients were further divided into two groups according to the extent of disease, as intrahepatic (n=153) or extrahepatic (n=138). Intrahepatic disease was defined as HCC confined to the liver parenchyma while extrahepatic disease included tumor involvement in the portal vein, lymph node, or distant sites. All clinical data of the enrolled patients were collected and managed using the Internet- 
Statistical Analysis
The primary end-point of this study was the duration of overall survival. It was measured from the start date of treatment to the date of death from any cause with surviving patients censored at the time of last follow-up.
ANOVA and independent sample t-test were used to compare TLR according to patient clinical characteristics. For univariate analysis, log-rank tests were performed using the following factors: age, gender, treatment, Child-Pugh classification, etiology of hepatitis, disease extent, tumor markers, and TLR from 18 F-FDG PET/CT. All continuous variables were dichotomized according to median cut-off values. For TLR, the optimal cut-off values were determined using receiver operating characteristic curve analysis. Cox proportional hazards regression tests in multivariate analysis were performed with variables that were significant in the univariate analyses. Survival curves were estimated using the Kaplan-Meier method, and differences between subgroups were compared with the log-rank test. Cumulative overall survival (OS) stratified by the TLR cutoff value was compared between the patients with intrahepatic and extrahepatic disease. All statistical analysis was performed using the statistical software, SPSS 19 version (SPSS Inc., Chicago, IL, United States), in which P <0.05 was considered statistically significant.
RESULTS
Patient Characteristics in Relation to
F-FDG uptake in Primary Tumors
The characteristics of 291 patients are shown in Table 1 . The mean age ± SD of the enrolled patients was 57.1 ± 10.5 y (range, 29-84 y). The mean interval between PET/CT scan and start of treatment was 5.8 days (range, 0-45 days). The treatments were as follows: in the intrahepatic disease group, 141 received local therapy and 12 systemic, compared to 91 and 47 in the extrahepatic, respectively. The median duration of follow-up was 6.3 months (range, 0.5-67.4 months). The mean TLR was 3.9 ± 2.1. The primary tumor showed significantly higher 18 F-FDG uptake in patients with extrahepatic disease (n = 138) compared to those with intrahepatic disease (n=153) (4.2 ± 2.2 vs. 3.6 ± 2.0, P = 0.018). Otherwise, there was no difference in TLR based on Child-Pugh classification, tumor size, tumor number, level of serum a-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II), presence of portal vein invasion, or treatment modality (local vs. systemic).
Prognostic Factor Analyses for Overall Survival
During follow-up, 250 of the 291 patients expired. The Kaplan-Meier estimate of 5-year OS was 6.9% with a median OS duration of 7.1 months. There was a significant difference in OS only according to the extent of disease, whether intrahepatic or extrahepatic (Figure 1 ; P < 0.001). Accordingly, the prognostic values of the variables were analyzed in two separate groups.
Age, gender, etiology, Child-Pugh classification, serum AFP and PIVKA-II level, tumor size and number, TLR and treatment modality were included in OS analysis (Table 2 and In patients with intrahepatic disease, Child-Pugh classification, PIVKA-II level, and TLR were significant for OS in univariate analysis (Table 2; all P < 0.05). In multivariate analysis, ChildPugh classification and TLR were independent prognostic factors for OS (both P < 0.05). High TLR was the most significant prognostic factor with a 1.89-fold increase in the risk of death (HR [hazard ratio] = 1.89; 95% confidence interval [CI], 1.3-2.73; P < 0.001, Table 2 ).
In patients with extrahepatic disease, Child-Pugh classification, tumor size, tumor number, portal vein invasion, and TLR were significant in univariate analysis (Table 3; all P < 0.05). Of these variables, TLR was the only independent prognostic factors for OS in multivariate analysis (both P < 0.05). In patients with TLR  3.2, there was a 1.69-fold increase in the risk of death (HR=1.69; 95% CI, 1.13-2.51; P = 0.01, Table 3, Figure 2 ).
Kaplan-Meier Survival Analyses according to Tumor
F-FDG Uptake
In patients with intrahepatic BCLC stage C, the median OS was different according to TLR; 14.9 months with TLR < 3.0 vs 6.4 months with TLR3.0 (P = 0.001, Table 4 ). In addition, prognostic stratification by TLR was also significantly different in patients with extrahepatic disease. The median OS was 7.7 months with TLR < 3.2 versus 4.3 months with TLR  3.2 (P = 0.003). Patients with intrahepatic disease and TLR < 3.0 in the primary tumor showed more than 3 times longer median OS than those with extrahepatic disease and TLR  3.2 (14.9 vs. 4.3 months). There was no significant difference in median OS between patients with intrahepatic disease but high TLR  3.0 and patients with extrahepatic disease but low TLR < 3.2 (P = 0.39, showed early recurrence after liver transplantation (20) (21) (22) . In a large, multicenter retrospective cohort of BCLC 0 and A patients undergoing curative treatment, those with a high TLR  2 had significantly worse OS than patients with a lower TLR < 2 (5-year OS, 61% vs. 79.4%) (23) .
TLR was an independent prognostic factor for progression free survival (PFS) and OS in patients with intermediate to advanced stage HCC confined to the liver (5). For advanced stage HCCs, one previous study showed the prognostic value of SUVmax for PFS and OS in 25 patients with extrahepatic metastasis (25) .
In the present study, we evaluated the prognostic value of clinical factors and TLR, tumor FDG uptake normalized to the liver on pretreatment 18 F-FDG PET/CT in 291 patients with solely BCLC stage C in a multicenter cohort. With a median overall survival of 7.1 months in all patients, we found a significant difference in OS according to the extent of disease. Median OS of the intrahepatic disease group was significantly longer than that of the extrahepatic (9 vs. 5.1 months). Within the same BCLC stage C, the prognosis of HCC was poor in the presence of extrahepatic metastasis similar to other solid tumors.
In the intrahepatic disease group, Child-Pugh classification, and TLR were independent prognostic factors for OS in multivariate analysis. Liver function variables such as Child-Pugh classification, but not TLR, are well-known factors in predicting prognosis (26) . In this study, we added TLR as a new metabolic prognostic variable for OS. Since TLR is reflective of tumor aggressiveness and rapid tumor proliferation (27,28), intrahepatic tumor progression with high TLR HCCs seems attributable to poor OS. Further studies are warranted to investigate whether therapeutic approaches to control intrahepatic tumors with high TLR can improve patient survival in intrahepatic BCLC stage C.
In the extrahepatic disease group, TLR was the only independent prognostics factors for OS in multivariate analysis. The mean TLR of patients with extrahepatic metastasis was significantly higher than that of patients without extrahepatic metastasis (4. There was a significant difference in OS between patients with intrahepatic and extrahepatic disease (9 months vs 5.1 months). It is likely that Child-Pugh classification may not have any remarkable prognostic significance in those with shorter survival.
One of the main findings of this study was the risk stratification using the extent of disease and TLR in primary HCC. In the intrahepatic disease group, the median OS was longer with a TLR < 3.0 than with a TLR  3.0 (14.9 vs. 6.4 months). In the extrahepatic disease group, the median OS was again longer with a TLR < 3.2 than with a TLR  3.2 (7.7 vs. 4.3 months). No significant difference in median OS was found between patients with intrahepatic disease and a TLR  3.0, and patients with extrahepatic disease and a TLR < 3.2. In our previous report, BCLC B or C patients treated with CCRT showed significantly better prognosis than those treated with TACE when the TLR was >2. In contrast, there was no difference in prognosis between patients treated with TACE or CCRT when the TLR was ≤2.0 (31). It has been suggested that There are several limitations of the current study. Although we selected patients in a large, multicenter, retrospective cohort, there might have been an inherent risk of selection bias adherent to the retrospective design. Second, different PET scanners were used from multiple medical centers. Although we did not perform PET/CT scanner calibration by phantom or qualification by any criteria, we centralized PET images from each center, verified image quality and measured parameters using the same software. Moreover, we used TLR normalized to the internal reference organ of the liver instead of SUVmax to reduce problems related to different scanners.
CONCLUSION
In patients with BCLC stage C HCC, 
